ERBB2 and cancer: Further validation of our results in other models of HER2 overexpressing and TZ resistant breast cancers such as MDA-MB-453, MDA-MB-361 or UACC893 would be crucial in order to determine if this combination is broadly effective in TZ resistant cancers.